arGentis Pharmaceuticals ( chose Target Health ( as its CRO partner for upcoming clinical trials. Utilizing the company’s expertise across multiple therapeutic categories will allow arGentis to expand development capacity without requiring an increase in staff or facilities, explains Tom Davis arGentis CEO.
arGentis licensed two transdermal therapies for the treatment of dry eye syndrome (DES) from the Southern College of Optometry in 2006. The company plans to submit an IND application to FDA on both products in the fourth quarter of 2007. Target Health will assist in this filing and provide all regulatory and quality deliverables throughout the clinical trial process.

Previous articlePfizer Gets Thumbs Up from EMEA’s Advisory Panel for HIV Drug
Next articleRentschler Adds Two 500-L Manufacturing Suites as Part of Expansion Project